Getting to NO Alzheimer's disease: Neuroprotection versus neurotoxicity mediated by nitric oxide

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Balez, Rachelle ^a   Ooi, Lezanne ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEURONS; NITRIC OXIDE;

ALZHEIMER'S DISEASE; BEHAVIORAL CHANGES; IONIC MECHANISMS; NEURODEGENERATIVE DISORDERS; NEUROINFLAMMATION; POTENTIAL MECHANISM; SIGNALING PATHWAYS; VOLTAGE-GATED POTASSIUM CHANNELS;

NEURODEGENERATIVE DISEASES;

AMYLOID BETA PROTEIN; CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SHAB POTASSIUM CHANNEL; TAU PROTEIN; VOLTAGE GATED POTASSIUM CHANNEL; NEUROPROTECTIVE AGENT; NEUROTOXIN;

ALZHEIMER DISEASE; AMNESIA; BEHAVIOR CHANGE; DISEASE COURSE; HUMAN; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; POTASSIUM CURRENT; PROTEIN EXPRESSION; REVIEW; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; SYNAPSE; TAUOPATHY; BRAIN; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; BRAIN; HUMANS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NITRIC OXIDE; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 84949969049     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/3806157     Document Type: Review

References (72)

1. C. Reitz, C. Brayne, and R. Mayeux, "Epidemiology of Alzheimer disease," Nature Reviews Neurology, vol. 7, no. 3, pp. 137-152, 2011.
2. A. Wimo, L. Jönsson, J. Bond, M. Prince, and B. Winblad, "The worldwide economic impact of dementia 2010," Alzheimer's and Dementia, vol. 9, no. 1, pp. 1-11, 2013.
3. W. Ties and L. Bleiler, "2012 Alzheimer's disease facts and fgures," Alzheimer's and Dementia, vol. 8, no. 2, pp. 131-168, 2012.
4. D. A. Casey, D. Antimisiaris, and J. O'Brien, "Drugs for Alzheimer's disease: are they efective?" Pharmacology & Ter-apeutics, vol. 35, no. 4, pp. 208-211, 2010.
5. J. Poirier, J. Davignon, D. Bouthillier, S. Kogan, P. Bertrand, and S. Gauthier, "Apolipoprotein E polymorphism and Alzheimer's disease," The Lancet, vol. 342, no. 8873, pp. 697-699, 1993.
6. C. Haass, C. A. Lemere, A. Capell et al., "The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway," Nature Medicine, vol. 1, no. 12, pp. 1291-1296, 1995.
7. B. De Strooper, T. Iwatsubo, and M. S. Wolfe, "Presenilins and γ-secretase: structure, function, and role in Alzheimer disease," Cold Spring Harbor Perspectives in Medicine, vol. 2, Article ID a006304, 2012.
8. H. W. Querfurth and F. M. LaFerla, "Alzheimer's disease," The New England Journal of Medicine, vol. 362, no. 4, pp. 329-344, 2010.
9. D. A. Butterfeld, J. Drake, C. Pocernich, and A. Castegna, "Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide," Trends in Molecular Medicine, vol. 7, no. 12, pp. 548-554, 2001.
10. M. Goedert, M. G. Spillantini, N. J. Cairns, and R. A. Crowther, "Tau proteins of Alzheimer paired helical flaments: abnormal phosphorylation of all six brain isoforms," Neuron, vol. 8, no. 1, pp. 159-168, 1992.
11. L. Messing, J. M. Decker, M. Joseph, E. Mandelkow, and E.-M. Mandelkow, "Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors," Neurobi-ology of Aging, vol. 34, no. 5, pp. 1343-1354, 2013.
12. M. Padurariu, A. Ciobica, R. Lefer, I. L. Serban, C. Stefanescu, and R. Chirita, "The oxidative stress hypothesis in Alzheimer's disease," Psychiatria Danubina, vol. 25, no. 4, pp. 401-409, 2013.
13. M. Schrag, C. Mueller, M. Zabel et al., "Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis," Neurobiology of Disease, vol. 59, pp. 100-110, 2013.
14. T. T. Reed, W. M. Pierce Jr., D. M. Turner, W. R. Markesbery, and D. Allan Butterfeld, "Proteomic identifcation of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule," Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 2019-2029, 2009.
15. M. A. Smith, P. L. Richey Harris, L. M. Sayre, J. S. Beckman, and G. Perry, "Widespread peroxynitrite-mediated damage in Alzheimer's disease," The Journal of Neuroscience, vol. 17, no. 8, pp. 2653-2657, 1997.
16. M. P. Mattson, "Oxidative stress, perturbed calcium homeosta-sis, and immune dysfunction in Alzheimer's disease," Journal of NeuroVirology, vol. 8, no. 6, pp. 539-550, 2002.
17. X. Wang, W. Wang, L. Li, G. Perry, H. Lee, and X. Zhu, "Oxidative stress and mitochondrial dysfunction in Alzheimer's disease," in Mitochondrial Dysfunction in Neurodegenerative Disorders, vol. 1842, pp. 1240-1247, 2014.
18. J. T. Coyle, D. L. Price, and M. R. DeLong, "Alzheimer's disease: a disorder of cortical cholinergic innervation," Science, vol. 219, no. 4589, pp. 1184-1190, 1983.
19. K. Mullane and M. Williams, "Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?" Biochemical Pharmacology, vol. 85, no. 3, pp. 289-305, 2013.
20. A. M. Hake, "Use of cholinesterase inhibitors for treatment of Alzheimer disease," Cleveland Clinic Journal of Medicine, vol. 68, no. 7, pp. 608-616, 2001.
21. A. Montagne, S. R. Barnes, M. D. Sweeney et al., "Blood-Brain barrier breakdown in the aging human hippocampus," Neuron, vol. 85, no. 2, pp. 296-302, 2015.
22. A. V. R. Santhanam, L. V. d'Uscio, T. He, P. Das, S. G. Younkin, and Z. S. Katusic, "Uncoupling of endothelial nitric oxide synthase in cerebral vasculature of Tg2576 mice," Journal of Neurochemistry, 2015.
23. T. Nakamura, S. Tu, M. W. Akhtar, C. R. Sunico, S.-I. Okamoto, and S. A. Lipton, "Aberrant protein S-nitrosylation in neurode-generative diseases," Neuron, vol. 78, no. 4, pp. 596-614, 2013.
24. K. Hensley, M. L. Maidt, Z. Yu, H. Sang, W. R. Markesbery, and R. A. Floyd, "Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specifc accumulation," The Journal of Neuroscience, vol. 18, no. 20, pp. 8126-8132, 1998.
25. 2-reaction," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 20, pp. 12691-12696, 2002.
26. T. Malinski, "Nitric oxide and nitroxidative stress in Alzheimer's disease," Journal of Alzheimer's Disease, vol. 11, no. 2, pp. 207-218, 2007.
27. D. A. Geller and T. R. Billiar, "Molecular biology of nitric oxide synthases," Cancer and Metastasis Reviews, vol. 17, no. 1, pp. 7-23, 1998.
28. J. Beckman and J. H. Tsai, "Reactions and difusion of nitric oxide and peroxynitrite," Biochemist, vol. 16, pp. 8-10, 1994.
29. A. Law, S. Gauthier, and R. Quirion, "Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type," Brain Research Reviews, vol. 35, no. 1, pp. 73-96, 2001.
30. R. M. Santos, C. F. Lourenço, A. Ledo, R. M. Barbosa, and J. Laranjinha, "Nitric oxide inactivation mechanisms in the brain: role in bioenergetics and neurodegeneration," International Journal of Cell Biology, vol. 2012, Article ID 391914, 13 pages, 2012.
31. J. R. Steinert, T. Chernova, and I. D. Forsythe, "Nitric oxide signaling in brain function, dysfunction, and dementia," The Neuroscientist, vol. 16, no. 4, pp. 435-452, 2010.
32. O. Arancio, V. Lev-Ram, R. Y. Tsien, E. R. Kandel, and R. D. Hawkins, "Nitric oxide acts as a retrograde messenger during long-term potentiation in cultured hippocampal neurons," Journal of Physiology Paris, vol. 90, no. 5-6, pp. 321-322, 1996.
33. D. K. Ditlevsen, L. B. Køhler, V. Berezin, and E. Bock, "Cyclic guanosine monophosphate signalling pathway plays a role in neural cell adhesion molecule-mediated neurite outgrowth and survival," Journal of Neuroscience Research, vol. 85, no. 4, pp. 703-711, 2007.
34. S. Kohgami, T. Ogata, T. Morino, H. Yamamoto, and P. Schubert, "Pharmacological shif of the ambiguous nitric oxide action from neurotoxicity to cyclic GMP-mediated protection," Neurological Research, vol. 32, no. 9, pp. 938-944, 2010.
35. T. J. O'Dell, R. D. Hawkins, E. R. Kandel, and O. Arancio, "Tests of the roles of two difusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11285-11289, 1991.
36. I. Bezprozvanny and M. P. Mattson, "Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease," Trends in Neurosciences, vol. 31, no. 9, pp. 454-463, 2008.
37. F. X. Guix, T. Wahle, K. Vennekens et al., "Modifcation of β-secretase by nitrosative stress links neuronal ageing to sporadic Alzheimer's disease," EMBO Molecular Medicine, vol. 4, no. 7, pp. 660-673, 2012.
38. R. Sultana, H. F. Poon, J. Cai et al., "Identifcation of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach," Neurobiology of Disease, vol. 22, no. 1, pp. 76-87, 2006.
39. P. Fernández-Vizarra, A. P. Fernández, S. Castro-Blanco et al., "Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease," Neurobiology of Disease, vol. 15, no. 2, pp. 287-305, 2004.
40. T. Malinski and I. Huk, "UNIT 7.14 measurement of nitric oxide in single cells and tissue using a porphyrinic microsenso," in Current Protocols in Neuroscience, chapter 7, John Wiley & Sons, 2001.
41. Š. Mesárǒs, Ž. Vaňková, S. Grunfeld, A. Mesárǒsová, and T. Malinski, "Preparation and optimization of superoxide microbiosensor," Analytica Chimica Acta, vol. 358, no. 1, pp. 27-33, 1998.
42. B. Winblad and N. Poritis, "Memantine in severe dementia, results of the 9M-best study (beneft and efcacy in severly demented patients during treatment with memantine)," International Journal of Geriatric Psychiatry, vol. 14, no. 2, pp. 135-146, 1999.
43. G. Collingridge, "Synaptic plasticity. The role of NMDA receptors in learning and memory," Nature, vol. 330, no. 6149, pp. 604-605, 1987.
44. X. Zhou, D. Hollern, J. Liao, E. Andrechek, and H. Wang, "NMDA receptor-mediated excitotoxicity depends on the coac-tivation of synaptic and extrasynaptic receptors," Cell Death and Disease, vol. 4, no. 3, article e560, 2013.
45. E. M. Schuman and D. V. Madison, "A requirement for the intercellular messenger nitric oxide in long-term potentiation," Science, vol. 254, no. 5037, pp. 1503-1506, 1991.
46. D. T. Chalmers, D. Dewar, D. I. Graham, D. N. Brooks, and J. McCulloch, "Diferential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type," Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 4, pp. 1352-1356, 1990.
47. N. Pomara, R. Singh, D. Deptula, J. C.-Y. Chou, M. B. Schwartz, and P. A. LeWitt, "Glutamate and other CSF amino acids in Alzheimer's disease," American Journal of Psychiatry, vol. 149, no. 2, pp. 251-254, 1992.
48. G. C. Brown, "Nitric oxide and neuronal death," Nitric Oxide, vol. 23, no. 3, pp. 153-165, 2010.
49. D. R. P. Brown, D. J. Wyper, J. Owens et al., "123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activiation in Alzheimer's disease," Journal of Psychiatric Research, vol. 31, no. 6, pp. 605-619, 1997.
50. C. Nathan, N. Calingasan, J. Nezezon et al., "Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase," Journal of Experimental Medicine, vol. 202, no. 9, pp. 1163-1169, 2005.
51. M. N. Wallace, J. G. Geddes, D. A. Farquhar, and M. R. Masson, "Nitric oxide synthase in reactive astrocytes adjacent to β-amyloid plaques," Experimental Neurology, vol. 144, no. 2, pp. 266-272, 1997.
52. B. A. Yankner, L. K. Dufy, and D. A. Kirschner, "Neurotrophic and neurotoxic efects of amyloid beta protein: reversal by tachykinin neuropeptides," Science, vol. 250, no. 4978, pp. 279-282, 1990.
53. M. Takahashi, Y. Chin, T. Nonaka, M. Hasegawa, N. Watanabe, and T. Arai, "Prolonged nitric oxide treatment induces tau aggregation in SH-SY5Y cells," Neuroscience Letters, vol. 510, no. 1, pp. 48-52, 2012.
54. S. T. DeKosky and S. W. Schef, "Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity," Annals of Neurology, vol. 27, no. 5, pp. 457-464, 1990.
55. R. D. Terry, E. Masliah, D. P. Salmon et al., "Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment," Annals of Neurology, vol. 30, no. 4, pp. 572-580, 1991.
56. S. Chakroborty, J. Kim, C. Schneider, A. R. West, and G. E. Stutzmann, "Nitric oxide signaling is recruited as a compensatory mechanism for sustaining synaptic plasticity in Alzheimer's disease mice," The Journal of Neuroscience, vol. 35, no. 17, pp. 6893-6902, 2015.
57. N. Gamper and L. Ooi, "Redox and nitric oxide-mediated regulation of sensory neuron ion channel function," Antioxidants and Redox Signaling, vol. 22, no. 6, pp. 486-504, 2015.
58. + channels mediates reciprocal channel modulation by nitric oxide and reactive oxygen species," Journal of Neuroscience, vol. 33, no. 14, pp. 6041-6046, 2013.
59. T. S. Surti and L. Y. Jan, "A potassium channel, the M-channel, as a therapeutic target," Current Opinion in Investigational Drugs, vol. 6, no. 7, pp. 704-711, 2005.
60. M. J. Kan, J. E. Lee, J. G. Wilson et al., "Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease," The Journal of Neuroscience, vol. 35, no. 15, pp. 5969-5982, 2015.
61. K. Baruch, A. Kertser, Z. Porat, and M. Schwartz, "Cerebral nitric oxide represses choroid plexus NF B-dependent gateway activity for leukocyte trafcking," The EMBO Journal, vol. 34, no. 13, pp. 1816-1828, 2015.
62. H. Javed, M. M. Khan, A. Ahmad et al., "Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinfammation in rat model of sporadic dementia of Alzheimer type," Neuroscience, vol. 210, pp. 340-352, 2012.
63. P.-X. Xu, S.-W. Wang, X.-L. Yu et al., "Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroin-fammation," Behavioural Brain Research, vol. 264, pp. 173-180, 2014.
64. L. Ooi, K. Sidhu, A. Poljak et al., "Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease," Journal of Neural Transmission, vol. 120, no. 1, pp. 103-111, 2013.
65. B. T. Hyman, K. Marzlof, J. J. Wenniger, T. M. Dawson, D. S. Bredt, and S. H. Snyder, "Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease," Annals of Neurology, vol. 32, no. 6, pp. 818-820, 1992.
66. M.-A. Dorheim, W. R. Tracey, J. S. Pollock, and P. Grammas, "Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease," Biochemical and Biophysical Research Communications, vol. 205, no. 1, pp. 659-665, 1994.
67. W. C. Benzing and E. J. Mufson, "Increased number of NADPH-d-positive neurons within the substantia innominata in Alzheimer's disease," Brain Research, vol. 670, no. 2, pp. 351-355, 1995.
68. P. J. Norris, R. L. M. Faull, and P. C. Emson, "Neuronal nitric oxide synthase (nNOS) mRNA expression and NADPH-diaphorase staining in the frontal cortex, visual cortex and hippocampus of control and Alzheimer's disease brains," Molecular Brain Research, vol. 41, no. 1-2, pp. 36-49, 1996.
69. L. Gargiulo, M. Bermejo, and A. Liras, "Reduced neuronal nitric oxide synthetase and C protein kinase levels in Alzheimer's disease," Revista de Neurologia, vol. 30, no. 4, pp. 301-303, 2000.
70. H.-J. Lüth, M. Holzer, U. Gärtner, M. Staufenbiel, and T. Arendt, "Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and afer experimental brain lesion in rat: evidence for an induction by amyloid pathology," Brain Research, vol. 913, no. 1, pp. 57-67, 2001.
71. G. Venturini, M. Colasanti, T. Persichini et al., "β-Amyloid inhibits NOS activity by subtracting NADPH availability," The FASEB Jour nal, vol. 16, no. 14, pp. 1970-1972, 2002.
72. M. Y. Stepanichev, M. V. Onufriev, A. A. Yakovlev et al., "Amyloid-β (25-35) increases activity of neuronal NO-synthase in rat brain," Neurochemistry International, vol. 52, no. 6, pp. 1114-1124, 2008.